Lorlatinib: A Targeted Therapy for ALK-Positive Lung Cancer Lorlatinib is a next-generation tyrosine kinase inhibitor (TKI) designed to treat ALK-positive non-small cell lung cancer (NSCLC). Approved by the FDA and…
What is Niraparib? Niraparib is an oral medication classified as a PARP inhibitor (Poly ADP-ribose polymerase inhibitor). It works by blocking the repair of damaged DNA in cancer cells, which…
What is Capmatinib? | Uses, Side Effects, and More Capmatinib (brand name: Tabrecta) is a targeted cancer therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). It…
Gilteritinib: Targeted Therapy for FLT3-Mutated AML Gilteritinib is a breakthrough oral medication used in the treatment of acute myeloid leukemia (AML), specifically for patients with a FLT3 gene mutation. As…
Reviews
There are no reviews yet.